Loading
When an aeroplane crashes, an independent report explains why so it does not happen again. When a cancer drug programme is abandoned, nothing is written. Change that.
Programme discontinuations are announced in earnings calls with a sentence. A structured termination report (target and mechanism, models used, what was predicted versus observed in humans, pharmacokinetics achieved, toxicities, the decision rationale, and lessons) published within twelve months of discontinuation, under a standard template, would turn each failure into shared learning. Precedents: aviation safety reporting, and the few published examples such as the analysis of the anti-CD47 and Rova-T programmes.
Shares A machine-readable taxonomy of why cancer drugs fail, Compliance with results reporting at ClinicalTrials.gov, Failures are hidden, Knowledge reaches practice too slowly.
Shares A commons of shelved cancer drugs with their full data, open to new hypotheses, Compliance with results reporting at ClinicalTrials.gov, Failures are hidden.
Shares A machine-readable taxonomy of why cancer drugs fail, Compliance with results reporting at ClinicalTrials.gov, Failures are hidden.
Shares Compliance with results reporting at ClinicalTrials.gov, Failures are hidden, Knowledge reaches practice too slowly.
Shares A machine-readable taxonomy of why cancer drugs fail, Failures are hidden.
Shares Compliance with results reporting at ClinicalTrials.gov, Failures are hidden.
Shares Compliance with results reporting at ClinicalTrials.gov, Failures are hidden.
Shares Compliance with results reporting at ClinicalTrials.gov, Failures are hidden.